FGF23 induces left ventricular hypertrophy

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369

Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology

Lang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., Picard, M. H., Roman, M. J., Seward, J., Shanewise, J. S., et al. (2005) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2005.10.005 · Cited by 11,318

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart study

Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., & Castelli, W. P. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005313222203 · Cited by 5,699

Prevalence of Chronic Kidney Disease in the United States

Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007) · JAMA · doi:10.1001/jama.298.17.2038 · Cited by 4,895

Mutation of the mouse klotho gene leads to a syndrome resembling ageing

Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837

A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy

Molkentin, J. D., Lu, J., Antos, C. L., Markham, B. E., Richardson, J. A., Robbins, J. M., Grant, S. R., & Olson, E. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81573-1 · Cited by 2,566

Fibroblast growth factors.

Ornitz, D. M., & Itoh, N. (2001) · Genome biology · doi:10.1186/gb-2001-2-3-reviews3005 · Cited by 1,985

Cellular signaling by fibroblast growth factor receptors

Eswarakumar, V. P., Lax, I., & Schlessinger, J. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.001 · Cited by 1,923

Regulation of cardiac hypertrophy by intracellular signalling pathways

Heineke, J., & Molkentin, J. D. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1983 · Cited by 1,890

Receptor Specificity of the Fibroblast Growth Factor Family

Ornitz, D. M., Xu, J., Colvin, J. S., McEwen, D. G., MacArthur, C. A., Coulier, F., Gao, G., & Goldfarb, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.25.15292 · Cited by 1,871

Investigating FGF-23 concentrations and its relationship with declining renal function in paediatric patients with pre-dialysis CKD Stages 3-5

Sinha, M. D., Turner, C., Dalton, R. N., Rasmussen, P., Waller, S. C., Booth, C. J., & Goldsmith, D. J. A. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs109 · Cited by 24

Effects of lovastatin treatment on the metabolic distributions in the Han:SPRD rat model of polycystic kidney disease

Klawitter, J., Zafar, I., Klawitter, J., Pennington, A. T., Klepacki, J., Gitomer, B. Y., Schrier, R. W., Christians, U., & Edelstein, C. L. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-165 · Cited by 24

Fibroblast Growth Factor-23 Helps Explain the Biphasic Cardiovascular Effects of Vitamin D in Chronic Kidney Disease

Hu, P., Xuan, Q., Hu, B., Lu, L., Wang, J., & Qin, Y. H. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.3886 · Cited by 24

Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification

Bover, J., Ureña, P., Lloret, M. J., Ruiz-García, C., daSilva, I., Encarnación, M. M. D., Mercado, C., Mateu, S., Fernández, E., & Ballarín, J. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1182155 · Cited by 24

The FGF23–Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease—a prospective cohort study

Lindblad, Y. T., Olauson, H., Vavilis, G., Hammar, U., Herthelius, M., Axelsson, J., & Barany, P. F. (2017) · Pediatric Nephrology · doi:10.1007/s00467-017-3766-5 · Cited by 24

FGF23 Synthesis and Activity

Noonan, M. L., & White, K. E. (2019) · Current Molecular Biology Reports · doi:10.1007/s40610-019-0111-8 · Cited by 24

Soluble Alpha-Klotho Alleviates Cardiac Fibrosis without Altering Cardiomyocytes Renewal

Chen, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062186 · Cited by 23

A Land of Controversy: Fibroblast Growth Factor-23 and Uremic Cardiac Hypertrophy

Bao, J., Hu, P., She, Q.-Y., & Li, A. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020010081 · Cited by 27

Roles of Parathyroid Hormone and Fibroblast Growth Factor 23 in Advanced Chronic Kidney Disease

Nakagawa, Y., & Komaba, H. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1978 · Cited by 23

FGF23, metabolic risk factors, and blood pressure in patients with primary hyperparathyroidism undergoing parathyroid adenomectomy

Nilsson, I., Norenstedt, S., Granath, F. N., Zedenius, J., Pernow, Y., & Larsson, T. E. (2015) · Surgery · doi:10.1016/j.surg.2015.06.057 · Cited by 23

Phosphate binding by sucroferric oxyhydroxide ameliorates renal injury in the remnant kidney model

Nemoto, Y., Kumagai, T., Ishizawa, K., Miura, Y., Shiraishi, T., Morimoto, C., Sakai, K., Omizo, H., Yamazaki, O., Tamura, Y., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-38389-3 · Cited by 23

Type I Interferon as cardiovascular risk factor in systemic and cutaneous lupus erythematosus: A systematic review

Kirchler, C., Husar-Memmer, E., Rappersberger, K., Thaler, K. J., & Fritsch-Stork, R. D. E. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102794 · Cited by 23

Expanded Haemodialysis as a Current Strategy to Remove Uremic Toxins

Ciceri, P., & Cozzolino, M. G. (2021) · Toxins · doi:10.3390/toxins13060380 · Cited by 23

Phosphate Absorption and Hyperphosphatemia Management in Kidney Disease: A Physiology-Based Review

Fishbane, S. N., & Nigwekar, S. U. (2021) · Kidney Medicine · doi:10.1016/j.xkme.2021.07.003 · Cited by 23

Vitamin D and Chronic Kidney Disease Association with Mineral and Bone Disorder: An Appraisal of Tangled Guidelines

Bover, J., Massó, E., Gifre, L., Alfieri, C., Soler-Majoral, J., Fusaro, M., Martínez, J. C., Rodríguez-Pena, R., Rodríguez, N., López‐Báez, V., et al. (2023) · Nutrients · doi:10.3390/nu15071576 · Cited by 23

Plasma levels of fibroblast growth factor‐23 are associated with muscle mass in haemodialysis patients

Fukasawa, H., Ishigaki, S., Kinoshita‐Katahashi, N., Niwa, H., Yasuda, H., Kumagai, H., & Furuya, R. (2014) · Nephrology · doi:10.1111/nep.12333 · Cited by 23

The FGF23/KLOTHO Regulatory Network and Its Roles in Human Disorders

Kinoshita, S., & Kawai, M. (2016) · Vitamins and hormones · doi:10.1016/bs.vh.2016.02.001 · Cited by 23

The Role of Klotho Protein in Chronic Kidney Disease: Studies in Animals and Humans

Gołembiewska, E., Pniewska, J., Kabat‐Koperska, J., dzierska, K. K., ski, M. D., & Ciechanowski, K. (2016) · Current Protein and Peptide Science · doi:10.2174/1389203717666160526123646 · Cited by 23

Sudden cardiac death in haemodialysis: clinical epidemiology and mechanisms

Banerjee, D. (2016) · Journal of Electrocardiology · doi:10.1016/j.jelectrocard.2016.07.016 · Cited by 23

Fibroblast Growth Factor-23, Heart Failure Risk, and Renin–Angiotensin–Aldosterone-System Blockade in Hypertension: The MESA Study

Akhabue, E., Vu, T. T., Vaidya, A., Michos, E. D., de Boer, I. H., Kestenbaum, B. R., Allison, M., Szklo, M., Ouyang, P., Yancy, C. W., et al. (2018) · American Journal of Hypertension · doi:10.1093/ajh/hpy142 · Cited by 23

Bone Marrow and Plasma FGF-23 in Heart Failure Patients: Novel Insights Into the Heart–Bone Axis

von Jeinsen, B., Sopova, K., Palapies, L., Leistner, D. M., Fichtlscherer, S., Seeger, F. H., Honold, J., Dimmeler, S., Aßmus, B., Zeiher, A. M., et al. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12416 · Cited by 23

Impaired function of fibroblast growth factor 23 / Klotho protein axis in prediabetes and diabetes mellitus: Promising predictor of cardiovascular risk

Berezin, A. Е., & Berezin, A. A. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.07.018 · Cited by 24

Modifying Phosphate Toxicity in Chronic Kidney Disease

Vervloet, M. G. (2019) · Toxins · doi:10.3390/toxins11090522 · Cited by 23

An expert update on novel therapeutic targets for hyperphosphatemia in chronic kidney disease: preclinical and clinical innovations

Cozzolino, M. G., Ketteler, M., & Wagner, C. A. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1743680 · Cited by 25

Fibroblast-Growth-Factor-23 in Heart Failure with Preserved Ejection Fraction: Relation to Exercise Capacity and Outcomes

Kanagala, P., Arnold, J. R., Khan, J. N., Singh, A., Gulsin, G. S., Eltayeb, M. M., Gupta, P., Squire, I. B., McCann, G. P., & Ng, L. L. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13020 · Cited by 23

A single preoperative FGF23 measurement is a strong predictor of outcome in patients undergoing elective cardiac surgery: a prospective observational study

Speer, T., Groesdonk, H. V., Zapf, B., Buescher, V., Beyse, M., Duerr, L., Gewert, S., Krauss, P., Poppleton, A., Wagenpfeil, S., et al. (2015) · Critical Care · doi:10.1186/s13054-015-0925-6 · Cited by 24

Fibroblast Growth Factor-23 and the Long-Term Risk of Hospital-Associated AKI among Community-Dwelling Older Individuals

Brown, J. R., Katz, R., Ix, J. H., de Boer, I. H., Siscovick, D. S., Grams, M. E., Shlipak, M. G., & Sarnak, M. J. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05830513 · Cited by 23

FGF23 in chronic kidney disease: Bridging the heart and anemia

Figurek, A., Rroji, M., & Spasovski, G. (2023) · Cells · doi:10.3390/cells12040609 · Cited by 22

From bone abnormalities to mineral metabolism dysregulation in autosomal dominant polycystic kidney disease

Mekahli, D., & Bacchetta, J. (2013) · Pediatric Nephrology · doi:10.1007/s00467-012-2384-5 · Cited by 23

FGF23: A Mature Renal and Cardiovascular Risk Factor?

Zoccali, C., Yılmaz, M. İ., & Mallamaci, F. (2013) · Blood Purification · doi:10.1159/000351001 · Cited by 22

Low-protein diets in chronic kidney disease: are we finally reaching a consensus?

Fouque, D. P., & Mitch, W. E. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu340 · Cited by 22

Change in FGF23 concentration over time and its association with all-cause mortality in patients treated with haemodialysis or haemodiafiltration

Krijger, A. B.-D., van Zuijdewijn, C. L. M. D. R., Nubé, M. J., Grooteman, M. P. C., Vervloet, M. G., the CONTRAST Study Group, Blankestijn, P. J., Grooteman, M. P. C., Nubé, M. J., ter Wee, P. M., et al. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa028 · Cited by 22

FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI

Song, T., Fu, Y., Wang, Y., Li, W., Zhao, J., Wang, X., Wang, H., Zhao, Y., & Fu, X. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01839-w · Cited by 22

Uremic Toxins and Cardiovascular System

Valkenburg, S., Glorieux, G., & Vanholder, R. C. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.04.002 · Cited by 22

A phosphate and calcium-enriched diet promotes progression of 5/6-nephrectomy-induced chronic kidney disease in C57BL/6 mice

Radloff, J., Latic, N., Pfeiffenberger, U., Schüler, C., Tangermann, S., Kenner, L., & Erben, R. G. (2021) · Scientific Reports · doi:10.1038/s41598-021-94264-8 · Cited by 22

The anti-aging factor Klotho protects against acquired long QT syndrome induced by uremia and promoted by fibroblast growth factor 23

Navarro‐García, J. A., Bodes, R. S., González‐Lafuente, L., Martín‐Nunes, L., Rodríguez‐Sánchez, E., Bada-Bosch, T., Hernández, E., Mérida-Herrero, E., Praga, M., Solı́s, J., et al. (2022) · BMC Medicine · doi:10.1186/s12916-021-02209-9 · Cited by 24

Impact of Ninjin’yoeito on frailty and short life in klotho-hypomorphic (kl/kl) mice

Amitani, H., Chiba, S., Amitani, M. S., Michihara, S., Takemoto, R., Han, L., Fujita, N., Takahashi, R., & Inui, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.973897 · Cited by 21

Osteocyte Egln1/Phd2 links oxygen sensing and biomineralization via FGF23

Noonan, M. L., Ni, P., Solis, E., Marambio, Y. G., Agoro, R., Chu, X., Wang, Y., Gao, H., Xuei, X., Clinkenbeard, E. L., et al. (2023) · Bone Research · doi:10.1038/s41413-022-00241-w · Cited by 25

A potential link between fibroblast growth factor-23 and the progression of AKI to CKD

Lu, Y., Xu, S., Tang, R., Han, C., & Zheng, C. (2023) · BMC Nephrology · doi:10.1186/s12882-023-03125-1 · Cited by 22

Removal of calciprotein particles from the blood using an adsorption column improves prognosis of hemodialysis miniature pigs

Miura, M., Miura, Y., Iwazu, Y., Mukai, H., Sugiura, T., Suzuki, Y., Kato, M., Kano, M., Nagata, D., Shiizaki, K., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-42273-0 · Cited by 22

Fibroblast Growth Factor 23 and Risk of Heart Failure Subtype: The CRIC (Chronic Renal Insufficiency Cohort) Study

Leidner, A. S., Cai, X., Zelnick, L. R., Lee, J. J., Bansal, N., Pasch, A., Kansal, M. M., Chen, J., Anderson, A. H., Sondheimer, J., et al. (2023) · Kidney Medicine · doi:10.1016/j.xkme.2023.100723 · Cited by 22

Are there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease?

Vo, T.-M. N., & Disthabanchong, S. (2014) · World Journal of Cardiology · doi:10.4330/wjc.v6.i5.216 · Cited by 22

Fibroblast Growth Factor 23 and Left Ventricular Mass Index in Maintenance Hemodialysis Patients: Standard Versus Long Nocturnal Hemodialysis

Knap, B., Večerić‐Haler, Ž., Benedik, M., Buturović‐Ponikvar, J., Ponikvar, R., & Bren, A. F. (2013) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12087 · Cited by 22

Plasma FGF23 levels and heart rate variability in patients with stage 5 CKD

Zhang, L.-N., Yang, G., Cheng, C., Shen, C., Cui, Y.-Y., Zhang, J., Zhang, J., Shen, Z., Zeng, M., Ge, Y.-F., et al. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2862-7 · Cited by 22

Impact of westernization on fibroblast growth factor 23 levels among individuals of African ancestry.

Eckberg, K., Kramer, H., Wolf, M., Durazo-Arvizu, R., Tayo, B., Luke, A., & Cooper, R. (2015) · Nephrology, Dialysis and Transplantation · doi:10.1093/ndt/gfu342 · Cited by 22

Gastrointestinal Phosphate Handling in CKD and Its Association With Cardiovascular Disease

Weinman, E. J., Light, P. D., & Suki, W. N. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.04.013 · Cited by 21

Regulation of Hormone-Sensitive Renal Phosphate Transport

Gattineni, J., & Friedman, P. A. (2015) · Vitamins and hormones · doi:10.1016/bs.vh.2015.01.002 · Cited by 23

Role of dietary phosphate restriction in chronic kidney disease

Elder, G. J., Malik, A., & Lambert, K. (2017) · Nephrology · doi:10.1111/nep.13188 · Cited by 22

High Fibroblast Growth Factor 23 concentrations in experimental renal failure impair calcium handling in cardiomyocytes

Verkaik, M., Oranje, M., Abdurrachim, D., Goebel, M., Gam, Z., Prompers, J. J., Helmes, M., ter Wee, P. M., van der Velden, J., Kuster, D. W. D., et al. (2018) · Physiological Reports · doi:10.14814/phy2.13591 · Cited by 22

Vitamin D and Calcimimetics in Cardiovascular Disease

Lim, K. J., Hamano, T., & Thadhani, R. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.02.005 · Cited by 22

Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature

Chakhtoura, M., Ramnitz, M. S., Khoury, N., Nemer, G. M., Shabb, N. S., Abchee, A., Berberi, A., Hourani, M., Collins, M. T., Ichikawa, S., et al. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4574-x · Cited by 22

Epoetin Beta and C‐Terminal Fibroblast Growth Factor 23 in Patients With Chronic Heart Failure and Chronic Kidney Disease

Eisenga, M. F., Emans, M. E., van der Putten, K., Cramer, M. J., Diepenbroek, A., Velthuis, B. K., Doevendans, P. A., Verhaar, M. C., Joles, J. A., Bakker, S. J. L., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011130 · Cited by 22

Voluntary Wheel Running Has Beneficial Effects in a Rat Model of CKD-Mineral Bone Disorder (CKD-MBD)

Avin, K. G., Allen, M. R., Chen, N. X., Srinivasan, S., O’Neill, K. D., Troutman, A. D., Mast, G., Swallow, E. A., Brown, M. B., Wallace, J. M., et al. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019040349 · Cited by 22

Association of hyperphosphatemia with an increased risk of sudden death in patients on hemodialysis: Ten-year outcomes of the Q-Cohort Study

Hiyamuta, H., Yamada, S., Taniguchi, M., Tokumoto, M., Tsuruya, K., Nakano, T., & Kitazono, T. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.11.020 · Cited by 22

Hypertension in Chronic Kidney Disease

Schaefer, F. S. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-824-9_22 · Cited by 22

Deletion of Soluble Epoxide Hydrolase Attenuates Cardiac Hypertrophy via Down-Regulation of Cardiac Fibroblasts–Derived Fibroblast Growth Factor-2

Zhang, H., Wang, T., Zhang, K., Liu, Y., Huang, F., Zhu, X., Liu, Y., Wang, M.-H., Tang, W., Wang, J., et al. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000226 · Cited by 22

FGF23 Actions in CKD-MBD and other Organs During CKD

Sun, T., & Yu, X. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220627122733 · Cited by 21

Serum Uric Acid Is Associated with Left Ventricular Hypertrophy Independent of Serum Parathyroid Hormone in Male Cardiac Patients

Fujita, S.-I., Okamoto, Y., Shibata, K., Morita, H., Ito, T., Sohmiya, K., Hoshiga, M., & Ishizaka, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082735 · Cited by 22

Correlates of left ventricular mass in chronic hemodialysis recipients

Wald, R., Goldstein, M. B., Wald, R. M., Harel, Z., Kirpalani, A., Perl, J. M., Yuen, D. A., Wolf, M. S., & Yan, A. T.-K. (2013) · International journal of cardiac imaging · doi:10.1007/s10554-013-0337-0 · Cited by 21

Should We Consider the Cardiovascular System While Evaluating CKD-MBD?

Rroji, M., Figurek, A., & Spasovski, G. B. (2020) · Toxins · doi:10.3390/toxins12030140 · Cited by 21

Comprehensive Expression Analysis of Cardiac Fibroblast Growth Factor 23 in Health and Pressure-induced Cardiac Hypertrophy

Eitner, F., Richter, B., Schwänen, S., Szaroszyk, M., Vogt, I., Grund, A., Thum, T., Heineke, J., Haffner, D., & Leifheit‐Nestler, M. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.791479 · Cited by 21

Insights into Concomitant Atrial Fibrillation and Chronic Kidney Disease

Wang, Y., Yang, Y., & He, F. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2303105 · Cited by 22

Fibroblast growth factor 23, klotho and heparin

Thomas, S. M., Li, Q., & Faul, C. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000895 · Cited by 22

The effects of vitamin D on different types of cells

Janubova, M., & Žitňanová, I. (2023) · Steroids · doi:10.1016/j.steroids.2023.109350 · Cited by 24

Fibroblast growth factor 23: friend or foe in uremia?

Moe, O. W. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64184 · Cited by 21

High serum phosphorus and FGF 23 levels are associated with progression of coronary calcifications

Srivaths, P. R., Goldstein, S. L., Krishnamurthy, R., & Silverstein, D. M. (2013) · Pediatric Nephrology · doi:10.1007/s00467-013-2575-8 · Cited by 21

Fibroblast growth factor 23 correlates with volume status in haemodialysis patients and is not reduced by haemodialysis

Humalda, J. K., Riphagen, I. J., Assa, S., Hummel, Y. M., Westerhuis, R., Vervloet, M. G., Voors, A. A., Navis, G. J., Franssen, C. F. M., & de Borst, M. H. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv393 · Cited by 21

Association of Left Ventricular Hypertrophy With a Faster Rate of Renal Function Decline in Elderly Patients With Non‐End‐Stage Renal Disease

Shi, H., Wang, X., Li, J., Song, G., Huang, Z., Guo, X., Guo, J., Lv, Z., Li, H., Ge, J., et al. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002213 · Cited by 21

The consequences of pediatric renal transplantation on bone metabolism and growth

Bacchetta, J., Ranchin, B., Demede, D., & Allard, L. (2013) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e3283651b21 · Cited by 22

Translational science in chronic kidney disease

Sánchez-Niño, M. D., Sanz, A. B., Ramos, A. M., Ruiz‐Ortega, M., & Ortíz, A. (2017) · Clinical Science · doi:10.1042/cs20160395 · Cited by 21

Pathophysiology and treatment of cardiovascular disease in pediatric chronic kidney disease

Khouzam, N. M., & Wesseling‐Perry, K. (2017) · Pediatric Nephrology · doi:10.1007/s00467-017-3798-x · Cited by 23

Controversies in the management of the haemodialysis-related arteriovenous fistula following kidney transplantation

Vanderweckene, P., Weekers, L. E., Lancellotti, P., & Jouret, F. (2017) · Clinical Kidney Journal · doi:10.1093/ckj/sfx113 · Cited by 21

Fibroblast growth factor23 is associated with axonal integrity and neural network architecture in the human frontal lobes

Marebwa, B., Adams, R. J., Magwood, G., Kindy, M. S., Wilmskoetter, J., Wolf, M. S., & Bonilha, L. (2018) · PLoS ONE · doi:10.1371/journal.pone.0203460 · Cited by 21

FGF23 and Klotho Levels are Independently Associated with Diabetic Foot Syndrome in Type 2 Diabetes Mellitus

Donate‐Correa, J., Martín‐Núñez, E., Ferri, C. M., Hernández-Carballo, C., Tagua, V. G., Delgado-Molinos, A., López-Castillo, Á., Rodriguez, S., Cerro-López, P., López-Tarruella, V. C., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8040448 · Cited by 21

Short-Term Effects of Very-Low-Phosphate and Low-Phosphate Diets on Fibroblast Growth Factor 23 in Hemodialysis Patients

Tsai, W., Wu, H., Peng, Y., Hsu, S., Chiu, Y., Yang, J., Chen, H., Pai, M., Lin, W., Hung, K., et al. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04250419 · Cited by 21

The tripartite interaction of phosphate, autophagy, and αKlotho in health maintenance

Shi, M., Maique, J., Shaffer, J., Davidson, T. L., Sebti, S., Fernández, Á. F., Zou, Z., Yan, S. X., Levine, B., Moe, O. W., et al. (2020) · The FASEB Journal · doi:10.1096/fj.201902127r · Cited by 20

MicroRNA-30 regulates left ventricular hypertrophy in chronic kidney disease

Bao, J., Lu, Y., She, Q.-Y., Dou, W., Tang, R., Xu, X., Zhang, M., Zhu, L., Zhou, Q., Li, H., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.138027 · Cited by 22

The role of fibroblast growth factor 23 in chronic kidney disease-mineral and bone disorder.

Diniz, H., & Frazão, J. M. (2013) · PubMed · doi:10.3265/nefrologia.pre2013.jul.12091 · Cited by 21

Uso del sevelamer en la enfermedad renal crónica. Más allá del control del fósforo

Rodríguez-Osorio, L., Zambrano, D. P., Gracia-Iguacel, C., Rojas-Rivera, J. E., Ortíz, A., Egido, J., & Parra, E. G. (2015) · Nefrología · doi:10.1016/j.nefro.2015.05.022 · Cited by 21

Mineral and bone disorders in kidney transplant recipients: reversible, irreversible, and de novo abnormalities

Hirukawa, T., Kakuta, T., Nakamura, M., & Fukagawa, M. (2015) · Clinical and Experimental Nephrology · doi:10.1007/s10157-015-1117-z · Cited by 21

Calcitriol Accelerates Vascular Calcification Irrespective of Vitamin K Status in a Rat Model of Chronic Kidney Disease with Hyperphosphatemia and Secondary Hyperparathyroidism

McCabe, K. M., Zelt, J. G. E., Kaufmann, M., Laverty, K. J., Ward, E., Barron, H., Jones, G., Adams, M. A., & Holden, R. M. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.247270 · Cited by 21

Left Ventricular Hypertrophy and Chronic Renal Insufficiency in the Elderly

Leibowitz, D. W. (2014) · Cardiorenal Medicine · doi:10.1159/000366455 · Cited by 20

Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy

Brener, A., Lebenthal, Y., Cleper, R., Kapusta, L., & Zeitlin, L. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211001150 · Cited by 20

Effect of a medium cut‐off dialyzer on protein‐bound uremic toxins and mineral metabolism markers in patients on hemodialysis

Tiong, M. K. D., Krishnasamy, R., Smith, E. R., Hutchison, C. A., Ryan, E., Pascoe, E. M., Hawley, C. M., Hewitson, T. D., Jardine, M., Roberts, M. A., et al. (2021) · Hemodialysis International · doi:10.1111/hdi.12924 · Cited by 20

Extracellular Vesicles and Their Relationship with the Heart–Kidney Axis, Uremia and Peritoneal Dialysis

Azevedo, C. A. B., da Cunha, R. S., Junho, C. V. C., da Silva, J. V., Moreno-Amaral, A. N., de Moraes, T. P., Carneiro‐Ramos, M. S., & Stinghen, A. E. M. (2021) · Toxins · doi:10.3390/toxins13110778 · Cited by 20

Fibroblast Growth Factor-23-Klotho Axis in Cardiorenal Syndrome: Mediators and Potential Therapeutic Targets

Navarro‐García, J. A., González‐Lafuente, L., Fernández‐Velasco, M., Ruilope, L. M., & Ruiz‐Hurtado, G. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.775029 · Cited by 21

Elevated parathyroid hormone one year after kidney transplantation is an independent risk factor for graft loss even without hypercalcemia

Okada, M., Tominaga, Y., Sato, T., Tomosugi, T., Futamura, K., Hiramitsu, T., Ichimori, T., Goto, N., Narumi, S., Kobayashi, T., et al. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02840-5 · Cited by 20

Updates in the chronic kidney disease-mineral bone disorder show the role of osteocytic proteins, a potential mechanism of the bone—Vascular paradox, a therapeutic target, and a biomarker

Williams, M. J., White, S. C., Joseph, Z., & Hruska, K. A. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1120308 · Cited by 23

Use of Vitamin D Receptor Activator, Incident Cardiovascular Disease and Death in a Cohort of Hemodialysis Patients

Shoji, T., Marubayashi, S., Shigematsu, T., Iseki, K., Tsubakihara, Y., & the Japanese Society for Dialysis Therapy (2014) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12274 · Cited by 20

Dietary and Pharmacological Modification of Fibroblast Growth Factor-23 in Chronic Kidney Disease

Adema, A. Y., de Borst, M. H., ter Wee, P. M., & Vervloet, M. G. (2013) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2013.09.001 · Cited by 18

Cardiac remodeling associated with protein increase and lipid accumulation in early-stage chronic kidney disease in rats

Kuwahara, M., Bannai, K., Segawa, H., Miyamoto, K., & Yamato, H. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.026 · Cited by 20

Defining, Treating, and Understanding Chronic Kidney Disease—A Complex Disorder

Campbell, D., & Weir, M. R. (2015) · Journal of Clinical Hypertension · doi:10.1111/jch.12560 · Cited by 21

Carboxy-terminal fragment of fibroblast growth factor 23 induces heart hypertrophy in sickle cell disease

Courbebaisse, M., Mehel, H., Petit-Hoang, C., Ribeil, J., Sabbah, L., Tuloup-Minguez, V., Bergerat, D., Arlet, J., Stanislas, A., Souberbielle, J., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.150987 · Cited by 20

The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study

Ogata, E., Kumasawa, J., Fukuma, S., Mizobuchi, M., Kinugasa, E., Fukagawa, M., Fukuhara, S., & Akizawa, T. (2017) · Clinical and Experimental Nephrology · doi:10.1007/s10157-017-1380-2 · Cited by 20

Fibroblast Growth Factor 23: A Biomarker of Kidney Function Decline

Drew, D. A., Katz, R., Kritchevsky, S. B., Ix, J. H., Shlipak, M. G., Newman, A. B., Hoofnagle, A. N., Fried, L. F., Sarnak, M. J., & Gutiérrez, O. M. (2018) · American Journal of Nephrology · doi:10.1159/000488361 · Cited by 20

Klotho is upregulated in human cardiomyopathy independently of circulating Klotho levels

Poelzl, G., Ghadge, S. K., Messner, M., Haubner, B. J., Würtinger, P., Griesmacher, A., Doerler, J., Ensinger, C., Ulmer, H., & Zaruba, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-26539-6 · Cited by 20

Fibroblast growth factor 23 and phosphate homeostasis

Balani, S. S., & Perwad, F. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000526 · Cited by 20

Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension

Bouzina, H., Hesselstrand, R., & Rådegran, G. (2019) · Pulmonary Circulation · doi:10.1177/2045894019895446 · Cited by 20

Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial

Patel, R. B., Mehta, R. C., Redfield, M. M., Borlaug, B. A., Hernandez, A. F., Shah, S. J., & Dubin, R. F. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.01.003 · Cited by 20

PF-06869206 is a selective inhibitor of renal Pitransport: evidence from in vitro and in vivo studies

Thomas, L., Xue, J., Tomilin, V. N., Pochynyuk, O. M., Rieg, J. A. D., & Rieg, T. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00146.2020 · Cited by 20

Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease

Leifheit‐Nestler, M., Siemer, R. G., Flasbart, K., Richter, B., Kirchhoff, F., Ziegler, W. H., Klintschar, M., Becker, J. U., Erbersdobler, A., Aufricht, C., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv421 · Cited by 207

Connecting the dots on fibroblast growth factor 23 and left ventricular hypertrophy

Gutiérrez, O. M. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv445 · Cited by 5

SaO027CARDIO-PATHOLOGICAL EFFECTS OF FGF23 IN CKD ARE MEDIATED BY FGFR4

Grabner, A., Amaral, A. P., Singh, S., Schramm, K. J., Sloan, A. J., Kentrup, D., Reuter, S., Pavenstaedt, H., Marco, G. S. D., Wolf, M., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv150.04

FGF-23, Left Ventricular Hypertrophy, and Mortality in Patients With CKD

Hidaka, N., Inoue, K., Katô, H., Hoshino, Y., Koga, M., Kinoshita, Y., Takashi, Y., Makita, N., Fukumoto, S., Nangaku, M., et al. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100747 · Cited by 13

Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease

Gutiérrez, O. M., Januzzi, J. L., Isakova, T., Laliberte, K. A., Smith, K., Collerone, G., Sarwar, A., Hoffmann, U., Coglianese, E. E., Christenson, R. H., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.844506 · Cited by 843